Stereotaxis and CardioFocus have begun a collaboration agreement to move robotic pulsed field ablation (PFA) technology toward commercialization.

The collab combines both companies’ proprietary tech to speed commercial availability of the first robotic PFA solution to treat cardiac arrhythmias. CardioFocus’ Centauri PFA is a next-gen, CE-marked system that’s been used to treat more than 9,000 European patients. Clinical experience has been reported in over 40 publications showing high levels of procedural efficiency, durable cardiac lesions, and low complication rates.

Stereotaxis’ Robotic Magnetic Navigation (RMN) systems feature the safety and precision of advanced robotic tech in cardiac ablation procedures. Its clinical value has been demonstrated in over 150,000 cardiac ablation patients treated worldwide and over 500 publications.

The duo has successfully completed extensive bench and preclinical testing of Centauri and MAGiC, including recent pivotal studies that showed safe, efficient, and impressive lesion delivery, including deep durable lesions in ventricular tissue.

RELATED: First U.S. Robotic HD Mapping Procedures Completed with MAGiC Sweep Catheter

“We are excited to collaborate with CardioFocus to accelerate bringing robotic PFA to the Electrophysiology community,” said David Fischel, Stereotaxis chairman and CEO. “The precision, stability and safety profile of robotics with the efficiency and attractive lesions created by Centauri is a winning combination. We look forward to transitioning to first human use and advancing the regulatory process in the coming few months.”

The collaboration agreement supports advancing the joint solution to a clinical trial to facilitate regulatory compatibility and commercial availability of MAGiC and Centauri.

“The combination of our patented PFA waveform and the MAGiC catheter has the potential to improve patient lives,” said Stephan Ogilvie, CEO of CardioFocus. “Through rigorous scientific development, we have customized our proven PFA waveform for Stereotaxis’ RMN systems and anticipate the collaboration will advance patient care in electrophysiology.”